Literature DB >> 10025760

Mycophenolate mofetil in autoimmune and inflammatory skin disorders.

H C Nousari1, A Sragovich, A Kimyai-Asadi, D Orlinsky, G J Anhalt.   

Abstract

Mycophenolate mofetil (MMF) has been widely used as an immunosuppressant in organ transplantation. MMF has recently been added to therapeutic regimens for skin disorders. Expanding the use of MMF in dermatology, we describe additional patients with autoimmune and inflammatory skin diseases, including 4 cases of pemphigus vulgaris, 1 case of pemphigus foliaceus, 1 case of perineal and metastatic cutaneous Crohn's disease, 1 case of bullous pemphigoid and psoriasis, and 1 case of psoriasis. Most of these patients had refractory disease or had developed significant side effects to conventional therapy, including azathioprine, methotrexate, prednisone, cyclosporine, acitretin, PUVA, UVB, and tacrolimus. MMF was effective and well tolerated in all these patients. The dosages of MMF ranged from 500 mg twice daily (for psoriasis and Crohn's disease) to 1250mg twice daily (for 3 of 4 patients with pemphigus vulgaris). MMF is an effective and relatively safe immunosuppressant in autoimmune and inflammatory skin diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025760     DOI: 10.1016/s0190-9622(99)70203-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

1.  [Mycophenolate mofetil as effective therapy option in scarring pemphigoid].

Authors:  I Elser; D Selimovic; T Ruzicka; A Kuhn; M Megahed
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

2.  [IgA pemphigus. Successful treatment with mycophenolate mofetil].

Authors:  T Burchardt; A Büchau; T Ruzicka; M Megahed
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

3.  The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room.

Authors:  Hyunhee Park
Journal:  J Clin Aesthet Dermatol       Date:  2011-01

4.  Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice.

Authors:  C A Jonsson; H Carlsten
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

Review 5.  Recent advances in treatment strategies for atopic dermatitis.

Authors:  Thomas Christian Roos; Stefan Geuer; Sabine Roos; Harald Brost
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Mycophenolate mofetil in the treatment of systemic lupus erythematosus.

Authors:  Ali Sahin
Journal:  Eurasian J Med       Date:  2009-12

Review 7.  Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.

Authors:  Benjamin C Park; Seungyeon Jung; Steven T Chen; Anna K Dewan; Douglas B Johnson
Journal:  Am J Clin Dermatol       Date:  2022-06-16       Impact factor: 6.233

8.  Therapy of autoimmune bullous diseases.

Authors:  Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

9.  Misleading pustular plaques of the lower limbs during Crohn's disease: two case reports.

Authors:  David Farhi; Paul Duriez; Selim Aractingi; Jacques Cosnes; Kiarash Khosrotehrani
Journal:  J Med Case Rep       Date:  2007-10-03

10.  Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse Model.

Authors:  Qing-Kang Lv; Ju-Xiong Liu; Su-Nan Li; Ying-Jie Gao; Yan Lv; Zi-Peng Xu; Bing-Xu Huang; Shi-Yao Xu; Dong-Xue Yang; Ya-Long Zeng; Dian-Feng Liu; Wei Wang
Journal:  Int J Mol Sci       Date:  2015-11-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.